We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+4.18%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$13.8M
(+4.1%)
Cap. Flow
+$18M
Cap. Flow
% of AUM
5.13%
Top 10 Holdings %
Top 10 Hldgs %
37.4%
Holding
88
New
31
Increased
19
Reduced
18
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$9.29M |
| 2 |
Danaher
DHR
|
+$9.16M |
| 3 |
Zimmer Biomet
ZBH
|
+$8.78M |
| 4 |
Intellia Therapeutics
NTLA
|
+$7.38M |
| 5 |
Merck
MRK
|
+$6.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$8.76M |
| 2 |
Eli Lilly
LLY
|
+$8.44M |
| 3 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$8.37M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$7.83M |
| 5 |
AbbVie
ABBV
|
+$7.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.97% |
| 2 | Energy | 3% |
| 3 | Industrials | 0.97% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Precision BioSciences
DTIL
$207M
| – | – |
-4,667
| Closed | -$1.17M |
|
77
Encompass Health
EHC
$12.4B
| – | – |
-87,990
| Closed | -$5.79M |
|
78
eHealth
EHTH
$39.1M
| – | – |
-25,000
| Closed | -$1.76M |
|
79
Guardant Health
GH
$22.2B
| – | – |
-35,000
| Closed | -$4.51M |
|
80
HCA Healthcare
HCA
$89.1B
| – | – |
-20,000
| Closed | -$3.29M |
|
81
Johnson & Johnson
JNJ
$626B
| – | – |
-35,000
| Closed | -$5.51M |
|
82
Kiniksa Pharmaceuticals
KNSA
$6.07B
| – | – |
-135,000
| Closed | -$2.38M |
|
|
83
Eli Lilly
LLY
$1.08T
| – | – |
-50,000
| Closed | -$8.44M |
|
84
Lexicon Pharmaceuticals
LXRX
$1.08B
| – | – |
-300,000
| Closed | -$1.03M |
|
85
Progyny
PGNY
$2.04B
| – | – |
-40,000
| Closed | -$1.7M |
|
|
ITCI
86
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-30,000
| Closed | -$954K |
|
|
GWPH
87
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-72,500
| Closed | -$8.37M |
|
|
BHVN
88
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-15,000
| Closed | -$1.29M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q1 2021 Portfolio in Review
As of Q1 2021, Integral Health Asset Management held 88 positions worth $350M, up 4.1% from $336M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Integral Health Asset Management deployed $18M of net new capital in Q1 2021, opening 31 new positions and adding to 19 existing holdings. Its largest new stake was Centene: 150,000 shares worth $9.59M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Energy and Industrials.
On the sell side, the largest reduction was NEVRO CORP., an estimated $7.83M trimmed.
- Integral Health Asset Management's largest Q1 2021 buy was Centene: 150,000 shares worth $9.59M.
- Integral Health Asset Management added most to Intellia Therapeutics in Q1 2021, an estimated $7.38M increase.
- Integral Health Asset Management's biggest Q1 2021 reduction was NEVRO CORP., cutting an estimated $7.83M.
- Integral Health Asset Management fully exited Abbott in Q1 2021, selling an estimated $8.76M.
- Integral Health Asset Management's ten largest holdings make up 37% of its $350M portfolio in Q1 2021.
- Integral Health Asset Management opened 31 new positions and closed 19 in Q1 2021.
- Integral Health Asset Management's portfolio value rose 4.1% quarter-over-quarter to $350M.
Based on Integral Health Asset Management's 13F filing for Q1 2021, filed 10 May 2021.